Literature DB >> 19156432

[Leg ulcer in mixed connective tissue disease. Resolution during sitaxsentan therapy].

H Becker1, C Sunderkoetter, P Willeke, W Domschke, M Gaubitz, M Mohr.   

Abstract

Leg ulcers may result in serious morbidity in patients with connective tissue diseases and Raynaud's phenomenon (RP). We describe a 35-year-old woman with mixed connective tissue disease who suffered from leg ulcers refractory to iloprost. When the patient was treated with the selective endothelin A receptor antagonist sitaxsentan for pulmonary arterial hypertension, the ulcers improved within 4 weeks and resolved completely thereafter. In addition, severity of RP ameliorated markedly. Further evaluation of sitaxsentan in patients with connective tissue diseases suffering from ischemic skin ulcers is required.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19156432     DOI： 10.1007/s00393-008-0421-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


  9 in total

Review 1.  Endothelin and endothelin receptor antagonists in systemic rheumatic disease.

Authors:  Maureen D Mayes
Journal:  Arthritis Rheum       Date:  2003-05

Review 2.  Autoimmune ulceration of the leg.

Authors:  J B Goslen
Journal:  Clin Dermatol       Date:  1990 Jul-Dec       Impact factor: 3.541

3.  [Recommendations of the German Society of Rheumatology on therapy of Raynaud syndrome and acral ulcerations].

Authors:  G Riemekasten
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 4.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

5.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

6.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

Review 7.  Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis.

Authors:  C Sunderkötter; G Riemekasten
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

8.  Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  Reda E Girgis; Adaani E Frost; Nicholas S Hill; Evelyn M Horn; David Langleben; Vallerie V McLaughlin; Ronald J Oudiz; Ivan M Robbins; James R Seibold; Shelley Shapiro; Victor F Tapson; Robyn J Barst
Journal:  Ann Rheum Dis       Date:  2007-05-01       Impact factor: 19.103

Review 9.  How does endothelial cell injury start? The role of endothelin in systemic sclerosis.

Authors:  David Abraham; Oliver Distler
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.